MCAM and neoplasm: Our previous publication (Westrom et al.)was innovative, as it was the first to evaluate an anti-CD146 antibody, OI-3, as a carrier for the targeted delivery of beta-emitting 177Lu as a payload for potential anti-tumor effects in an osteosarcoma xenograft model14.